Menu
Close
Access & Support
Lorem ipsum dolor sit amet, consectetur badipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Optional footnote area for disclaimers etc.
Similar rates of systemic AEs observed between ABRYSVO and placebo groups5†
†The most common solicited local and systemic adverse reactions (≥10%) were fatigue (15.5%), headache (12.8%), pain at the injection site (10.5%), and muscle pain (10.1%).5
86% vaccine efficacy against RSV-LRTD with ≥3 symptoms (96.66% CI: 32.0, 98.7)5
67% vaccine efficacy against RSV-LRTD with ≥2 symptoms (96.66% CI: 28.8, 85.8)5
‡Interim data from season 1. The median duration of efficacy follow-up was 7 months. Evaluable efficacy population: ABRYSVO, n=16,306; placebo, n=16,308.5
Vaccinate your patients aged 60 years and older today with ABRYSVO5
The only RSV vaccine approved for both adults aged 60+ and pregnant individuals (at 32-36 weeks of gestation) for the protection of infants (from birth through 6 months) via maternal immunization5
Learn more about the maternal indication
See Pfizer's convenient, needle-free§ reconstitution kit5
§Needle required for intramuscular injection is not included.
Get the support you need and learn more about costs and coverage
Explore a range of resources related to ABRYSVO, including videos, information about upcoming events, and more.
Explore a range of resources related to ABRYSVO, including videos, information about upcoming events, and more.